Phenylpiracetam Overview, Dosing & Safety | Peptide Database

Phenylpiracetam (Phenotropil)

Racetam Nootropic | Cognitive & Physical Performance

Community Research

Join others researching Phenylpiracetam — share findings, ask questions, and learn from real experiences

Phenylpiracetam (also known as Phenotropil, Carphedon, or Fonturacetam) is a phenylated derivative of piracetam developed in Russia in 1983, originally for Soviet cosmonauts to enhance cognitive function, physical stamina, and cold tolerance during space missions. The addition of a phenyl group to piracetam's pyrrolidone nucleus fundamentally changes the compound's pharmacological profile -- it crosses the blood-brain barrier more readily, has significantly greater affinity for multiple neurotransmitter systems, and exhibits pronounced psychostimulant and physical performance-enhancing properties absent in piracetam. Phenylpiracetam was approved and marketed in Russia as Phenotropil for cognitive impairment, asthenia, and convulsive disorders until its manufacturer ceased production. It gained notoriety in the sporting world after the World Anti-Doping Agency (WADA) added it to the prohibited substances list following its detection in several Olympic athletes, confirming its reputation as a legitimate performance enhancer. One of its most distinctive properties is the enhancement of cold tolerance, a trait that directly reflects its origins as a cosmonaut support compound and has been demonstrated in animal models of hypothermia.

Phenylpiracetam modulates multiple neurotransmitter systems, which accounts for its broad spectrum of cognitive and physical effects. Like other racetams, it acts as a positive allosteric modulator of AMPA receptors, enhancing glutamatergic transmission and facilitating long-term potentiation in hippocampal circuits critical for memory formation. However, unlike piracetam, phenylpiracetam also significantly affects dopaminergic and noradrenergic signaling -- it increases the density of dopamine D1, D2, and D3 receptors and noradrenaline receptors in the striatum and other brain regions, which underpins its stimulant, mood-elevating, and motivation-enhancing properties. It also modulates nicotinic acetylcholine receptors and NMDA-type glutamate receptors, contributing to its procognitive effects. The phenyl group increases lipophilicity, allowing faster and more complete penetration of the blood-brain barrier compared to piracetam. Phenylpiracetam also demonstrates anticonvulsant activity and has been shown to reduce the threshold for cold-induced stress responses, likely through modulation of hypothalamic thermoregulatory circuits and peripheral adrenergic mechanisms. The compound's physical performance-enhancing effects are attributed to increased noradrenergic and dopaminergic tone, enhanced muscular endurance, and reduced perception of effort and fatigue.

Molecular Data

Research Indications

Phenylpiracetam enhances memory consolidation and retrieval through AMPA receptor modulation and increased dopaminergic signaling. Clinical studies in patients with cognitive impairment from organic brain disease and cerebrovascular conditions have shown statistically significant improvements in memory test scores.

The dopaminergic and noradrenergic activity of phenylpiracetam provides a clean stimulant effect that enhances sustained attention, task motivation, and mental stamina. This distinguishes it from piracetam and most other racetams, which lack meaningful stimulant properties.

Phenylpiracetam improves physical endurance, reduces perception of effort, and enhances exercise tolerance. These effects were significant enough to earn it a place on the WADA prohibited substances list. Athletes have reported improved stamina and recovery during competition.

Phenylpiracetam was approved in Russia for asthenia and chronic fatigue states of various origins. Clinical trials demonstrated improvements in subjective energy, motivation, and capacity for sustained mental and physical work in patients with post-infectious, cerebrovascular, and post-traumatic asthenia.

Approved for cognitive deficits associated with cerebrovascular disease. Patients showed improvements in memory, attention, and overall cognitive functioning, along with reductions in depression and anxiety.

Phenylpiracetam has demonstrated anticonvulsant properties in preclinical models and was included in the Russian clinical indication for adjunctive treatment of convulsive conditions.

Developed for Soviet cosmonauts to withstand extreme cold. Animal studies confirm that phenylpiracetam significantly increases resistance to hypothermia. This property is unique among the racetam family and has potential applications for military, aerospace, and extreme sports contexts.

The dopaminergic activity of phenylpiracetam provides mood-elevating effects that may benefit individuals with depression, particularly anhedonic subtypes. This remains investigational, with supporting evidence primarily from clinical observations and the known pharmacological profile rather than large-scale controlled trials.

Dosing Protocols

Phenylpiracetam is administered orally in capsule or tablet form. It is well absorbed from the gastrointestinal tract with a bioavailability of approximately 100%. The compound reaches peak plasma concentration within 1 hour of oral administration. It can be taken with or without food, though some users report slightly faster onset on an empty stomach.

Standard Cognitive Enhancement

100 mg

Once or twice daily (morning, or morning and early afternoon)

Oral capsule/tablet

Acute Performance (Physical or Cognitive)

200 mg

Single dose, 1-2 hours before event

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Insomnia, particularly if taken in the afternoon or evening -- the stimulant effects can persist for several hours after dosing

Irritability and overstimulation, especially at higher doses or when combined with other stimulants

Headache, most commonly caused by increased acetylcholine demand without adequate choline supplementation

Rapid tolerance development -- the most significant practical limitation, requiring intermittent dosing schedules to maintain efficacy

Stop Signs - Discontinue if:

Persistent insomnia that does not resolve with dosing time adjustment

Significant anxiety, agitation, or panic-like symptoms

Sustained elevated heart rate or blood pressure

Marked mood instability, depression, or emotional flatness

Contraindications

Known hypersensitivity to phenylpiracetam or other racetams

Severe hypertension or cardiovascular disease (due to stimulant properties)

Pregnancy and breastfeeding (insufficient safety data)

Severe hepatic or renal impairment

Competitive athletes subject to WADA testing (phenylpiracetam is a prohibited substance under Section S6: Stimulants)

Frequently Asked Questions

How much stronger is phenylpiracetam than piracetam?

Phenylpiracetam is approximately 30-60x more potent by weight than piracetam, meaning 100 mg of phenylpiracetam is roughly equivalent to 3-6 grams of piracetam in terms of nootropic effect. This dramatic potency increase comes from the addition of a phenyl group, which increases blood-brain barrier penetration and broadens the pharmacological profile to include dopaminergic and noradrenergic activity absent in piracetam.

Why does phenylpiracetam tolerance develop so fast?

Tolerance develops most quickly to the stimulant and motivational effects, often significantly reduced by day 5-7 of continuous use. The cognitive and focus benefits persist somewhat longer, but overall efficacy drops dramatically within a week of daily dosing. This rapid tolerance is the primary limitation of phenylpiracetam and why intermittent dosing (2-3x per week or short 1-2 week cycles) is essential to maintain effectiveness.

Is phenylpiracetam safe for competitive athletes?

Phenylpiracetam is prohibited by WADA under Section S6: Stimulants. Any competitive athlete subject to anti-doping testing should absolutely avoid phenylpiracetam, as it's easily detectable and will result in a failed test and potential bans. This prohibition reflects its genuine performance-enhancing properties in both cognitive and physical domains, which is why it was developed for Soviet cosmonauts.

Should I combine phenylpiracetam with caffeine?

Both are stimulants, so combining them produces additive effects. This works well for some users seeking maximum acute alertness, but others find the combination excessive, causing anxiety, jitteriness, or overstimulation. If you're sensitive to stimulants, take phenylpiracetam alone. If combining both, moderate the caffeine intake (half your usual dose) and monitor for signs of overstimulation.

References

Demonstrated that phenylpiracetam (Phenotropil) significantly improved cognitive function, memory, and attention in patients with chronic cerebrovascular insufficiency over a 30-day treatment course, with additional improvements in depressive and anxiety symptoms.

Comprehensive review of phenylpiracetam pharmacology demonstrating its effects on dopamine transporter (DAT) and norepinephrine transporter (NET), providing a mechanistic explanation for its stimulant and performance-enhancing properties distinct from piracetam.

The original publication characterizing phenylpiracetam's pharmacological profile, demonstrating its anticonvulsant, anxiolytic, and memory-enhancing effects in animal models, along with its significantly greater potency compared to piracetam.

Review covering racetam-family nootropics including phenylpiracetam, noting its unique physical performance-enhancing properties, enhanced cold tolerance, and the pharmacological basis for its inclusion on the WADA prohibited substances list.

Compared phenylpiracetam and piracetam in a model of cerebral ischemia, finding that phenylpiracetam provided significantly greater neuroprotection, reduced infarct volume, and improved behavioral outcomes, consistent with its enhanced potency and broader receptor activity.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.